XBI's Recovery Reflects Normalization of the Exit Market

The SPDR S&P Biotech ETF (XBI) rose from approximately $90 in August 2025 to around $170 in August 2026, entering record territory. Compared to the 2023 low of $64, the revaluation of biotech risk assets is evident. With both M&A and IPOs—two major venture capital exit routes—simultaneously opening, capital is concentrating on late-stage clinical companies. The recent rise is driven more by actual exit opportunities than mere interest rate expectations.

Large IPOs Validate Late-Stage Clinical Value

In 2026, biotech IPOs reached 20 deals, already surpassing the 11 deals of 2025, with 14 of them raising over $250 million. Veradermics, Incorporated (MANE) raised $256.3 million at $17 per share, with a total of approximately $766.8 million including follow-on offerings. Its lead candidate, VDPHL01, is an unspecified-name extended-release oral minoxidil that acts as a vasodilator by opening ATP-sensitive potassium channels. It has completed two Phase 3 registration trials for male pattern baldness and targets the 80 million U.S. patients and the $300 billion hair loss market by 2028. It directly competes with Rogaine (topical minoxidil) and Propecia (finasteride, a 5-alpha reductase inhibitor) as standard treatments.

Clinical Progress Creates Premium for Newly Listed Companies

Hemab Therapeutics Holdings (COAG)'s sutacimig (HMB-001) is a bispecific antibody linking activated coagulation factor VIIa with platelet TLT-1. It has completed Phase 1/2 trials for Glanzmann thrombasthenia and is scheduled to begin Phase 3 in the second half of 2026. The FDA granted its Breakthrough Therapy designation on March 5, 2026, along with Fast Track and Rare Disease designations, and EMA PRIME. Competitive treatments include NovoSeven (epoetin alfa) and platelet transfusions, so the convenience of subcutaneous prophylactic therapy is a key differentiator. Avalyn Pharma (AVLN)'s AP01, an inhaled pirfenidone, completed a 398-patient Phase 2b registration trial for progressive pulmonary fibrosis and challenges Ofev (nintedanib) and oral pirfenidone in the approximately $4 billion 2025 treatment market.

Patent Cliff Structurally Drives Large M&A

According to J.P. Morgan, biotech M&A in the first half of 2026 totaled 80 deals with combined upfront values of $96 billion, confirming a preference for approved or mid-to-late-stage assets. Eli Lilly and Company (LLY) agreed to acquire Kelonia Therapeutics, a Phase 1 in vivo CAR-T company, for up to $7 billion, including an upfront payment of $3.25 billion and contingent payments of $3.75 billion. GSK plc (GSK) acquired Nuvalent (NUVL), which holds the ROS1 inhibitor gedisametinib and ALK inhibitor nelarotenic, for $124 per share, totaling $10.6 billion in cash. With over $2 trillion in patent expirations from 2025 to 2030, the strategic scarcity of mid-sized biotech companies with reduced clinical risk is increasing.